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PURPOSE: To perform clinical and genetic screening for multiple endocrine neoplasia type 1 (MEN1) in patients at the Academic
Hospital of the University of São Paulo School of Medicine, and to analyze its impact on clinical management of patients with
MEN1.
METHODS: The clinical diagnosis of MEN1 was made in accordance with the Consensus on multiple endocrine neoplasias.
Mutation analysis of the entire MEN1 tumor suppressor gene and genetic screening of at-risk family members were performed by
direct sequencing. To analyze the implementation of genetic diagnosis, the studied patients were separated into 3 groups: MEN1
index cases (group I), clinically diagnosed MEN1 cases (group II), and genetically diagnosed MEN1 cases (group III).
RESULTS: In total, 154 individuals were clinically and genetically studied. We identified 12 different MEN1 mutations. Fifty-two
MEN1 cases were identified: 13 in group I, 28 in group II, and 11 in group III. The mean age in group III (27.0 years) was
significantly lower than in groups I (39.5 years) and II (42.4 years; P = 0.03 and P = 0.01, respectively). Patients in groups I and II
mostly presented 2 or 3 MEN1-related tumors, while 81.8% of those in group III presented 1 or no MEN1-related tumor. Additionally,
in group III, 45.4% of cases were asymptomatic, and no metastasis or death was verified. Surveillance for MEN1 mutations allowed
the exclusion of 102 noncarriers, including a case of MEN1 phenocopy.
CONCLUSION: Our data supports the benefits of clinical and genetic screening for multiple endocrine neoplasia type 1 in the
management of this syndrome.
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INTRODUCTION
Clinical Aspects of the MEN1 syndrome
Multiple endocrine neoplasia type 1 (MEN1; OMIM
131100) is an autosomal dominant inherited tumor syn-
drome mainly characterized by parathyroid, endocrine pan-
creas, and pituitary tumors.1,2 According to the MEN Con-
sensus (2001), the diagnosis of this condition is based on
the concomitant occurrence in a patient of at least 2 of these
3 major MEN1-related tumors.1
Hyperparathyroidism in MEN1
Primary hyperparathyroidism (HPT) is the most com-
mon clinical feature of MEN1, and it occurs in 73% to
100% of cases (Table 1). HPT is usually (80%) the first
clinical manifestation of MEN1.3 Primary hyperparathy-
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roidism due to MEN1 (HPT/MEN1) differs from sporadic
primary HPT (sHPT) in several aspects, as it presents, a)
multiglandular parathyroid hyperplasia or adenoma; b) age-
onset 2 decades earlier than sHPT (20 vs 40 years of age);
c) sex ratio of 1:1 in contrast to the 1:3 for sHPT; and d)
higher recurrence rates of HPT after parathyroidectomy.4,5
Although HPT/MEN1 tends to be less aggressive than
sHPT, usually presenting parathyroid hormone (PTH) rang-
ing from 2 to 3 times over the upper normal limits and mod-
erately high calcium levels,6 “moans, groans, and stones”
and renal insufficiency may occur in advanced stages of this
disease. In late diagnosed cases, renal dialysis and kidney
transplantation may be necessary.5
Surgical management for HPT/MEN1 includes subto-
tal or total parathyroidectomy followed by an autograph to
the forearm, clearly differing from the adenomectomy rec-
ommended for sHPT. Furthermore, in MEN1 cases, pre-
ventive thymectomy is recommended in association with
parathyroidectomy to prevent thymic carcinoids.1,7–10 These
facts underline the importance of performing the diagno-
sis of MEN1 for better management of HPT in these pa-
tients.7–10
The penetrance of HPT in MEN1 in several series has
been reported as high as 95% at 50 years of age, so it
has been considered the main clinical feature for the di-
agnosis of MEN1. Thus, screening for other MEN1-re-
lated diseases was initially considered less necessary for
recognition of MEN1. Screening for HPT in MEN1 was
usually performed only until 50 years of age. However,
recent series have shown lower prevalences (50%-70%)
of HPT as the first clinical characteristic in MEN1 and
lower HPT penetrance (70%) than previously reported.
These findings indicated that HPT surveillance should be
performed for longer periods.11,12
Endopancreatic tumors in MEN1
Pancreatic/duodenal endocrine tumors (PETs) occur in
up to 30% to 80% of patients with MEN1.3,13,14 Gastrinoma
in MEN1 is the most prevalent functioning PET, seen in
30% to 75% of MEN1 cases5. The gastrinomas in MEN1
mostly occur in the duodenum (up to 90%) and is frequently
multifocal, in contrast to unifocal sporadic gastrinomas.5
Furthermore, up to 25% of all gastrinomas are related to
MEN1.1,15 Surgical procedures in gastrinoma associated
with MEN1 are usually more extensive than those applied
to its sporadic counterpart. Enucleation of multiple nodules
of the duodenum associated with subtotal (80%-85%) pan-
createctomy is recommended for patients with MEN1,
whereas enucleation of the unique small tumor of the duo-
denum or pancreas and duodenectomy or partial pancrea-
tectomy for bigger tumors are usually performed for spo-
radic gastrinomas.16,17 Thus, the presurgical MEN1 diagno-
sis offers the surgeon important information for a better ap-
proach regarding PETs in MEN1 cases.
A similar statement was also applied to insulinoma as-
sociated with MEN1, which is the second most prevalent
functioning PET in MEN1 (10%-30%). For patients with
insulinoma due to MEN1, subtotal pancreatectomy com-
bined with enucleation of possible nodules of the head of
pancreas is the recommended surgical approach .1,5 Enu-
cleation of the unique nodule of the pancreas or partial pan-
createctomy are the most common surgical approaches to
sporadic insulinomas.
Pituitary tumors in MEN1
Pituitary adenomas have been documented in up to 40%
of MEN1 cases reported in extended series.18–20 However,
lower prevalences (18%-21%) have been also documented
by others.21,22 In 17% of MEN1 cases, a pituitary adenoma
may be the initial lesion.18 Interestingly, age at the diagno-
sis of pituitary tumors is similar (~37 yrs) for MEN1, fa-
milial isolated pituitary adenomas, and sporadic pituitary
tumors.18,23 Pituitary adenomas in MEN1 are usually more
aggressive and larger than in its sporadic counterpart. Thus,
up to 85% of pituitary tumors associated with MEN1 are
macroadenomas (32% invasive), in contrast to 42% in non-
MEN1 cases.18
Prolactinoma is the most frequent pituitary disease in
MEN1; 62% to 76% of patients with MEN1 having pitui-
tary disease present with prolactinoma, although nonsecreting
pituitary adenomas are also frequent (14%-24%).18,21 Co-se-
creting, GH-, and ACTH-secreting pituitary tumors are less
frequent (10%, 9%, and 4%, respectively),18 whereas FSH
and TSH-secreting tumors are both very rare in MEN1.24
Table 1 - Prevalence (%) of clinical features in MEN1
disease*
Endocrine Tumors
 Parathyroid adenoma (73-100) Anterior pituitary tumor (20-40)
Prolactinoma (62-76)
 Enteropancreatic tumor (30-80) NS (14-24)
Gastrinoma ** (30-75) Co-secreting (10)
Insulinoma (10-30) GH-secreting (9)
ACTH-secreting (4)
 Carcinoids ** (> 10) TSH-secreting ( rare )
Adrenal cortex NS (12-40)
Nonendocrine Tumors
 Facial angiofibroma (40-80)
*References 1,3,11,14,18–22
**tumor with malignant potential (> 25%); NS, nonsecreting.
MEN1 = multiple endocrine neoplasia type 1
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In addition to the major features of MEN1 mentioned
above, up to 20 other endocrine and nonendocrine tumors
have been described in association with MEN1 (Table 1).13
Due to its extended and widely variable phenotype, MEN1
is presently considered a complex, multisystemic disorder,
and its clinical diagnosis may turn to be a difficult task.13
Thymic carcinoid tumors and gastrinoma are the major
causes of death in MEN1 patients.25,26 More than 90% of
MEN1-associated thymic carcinoids are malignant;25–27 however,
these tumors are relatively rare. On the other hand, although
gastrinomas are usually less malignant (60%) than thymic
carcinoids,28 they can be detected in up to 75% of MEN1 cases
depending on the series (Table 1). Malignancies are responsi-
ble for significant lowering ages of death verified for MEN1
(55.4 years for men and 46.8 years for women), as compared
to life expectation in the general population (> 70 years).29
No preventive surgical approach has been shown to sig-
nificantly improve the outcome of MEN1.1 However, it is ac-
cepted that the earlier the identification of MEN1 neoplasias,
the better the clinical management of this disease.30,31 As rec-
ommended by the MEN Consensus, the suggested approach
for patients with MEN1 is based on periodical surveillance
of MEN1-related neoplasias that should begin as early as 5
to 20 years of age.1 Surveillance for MEN1 neoplasia is a
time-consuming, laborious, expensive, and lifelong procedure
that includes clinical, biochemical, and imaging investiga-
tions. However, it has been proven to be efficient in the iden-
tification of MEN1 tumors and in the reduction of morbid-
ity30 and mortality of patients with MEN1.25,26,31
Therefore, the establishment of a structured and long-
term follow-up program focused on screening for MEN1
would be a worthwhile effort.29
Genetic Aspects of MEN1
Familial MEN1 is an autosomal dominantly inherited dis-
ease presenting almost complete penetrance.13 The gene re-
sponsible for MEN1 (MEN1) was identified at 11q13 by two
different research groups, one from NIH32 and another from
the European Consortium.33 Since genetic screening for
MEN1 became available, more than 400 germline and so-
matic mutations have been identified in this gene.13,34 Most
MEN1 mutations are inactivating, nonsense, or frameshift
variants. Although splicing mutations represent only 5% of
the overall mutations identified in the MEN1 gene,34 some
of these disease-causing variants can be frequently found.35
Furthermore, several missense MEN1 mutations have been
identified, mostly occurring in evolutionary conserved sites,
predicted to be related to retained relevant functions (Toledo
RA et al., Clin Endocrinol (Oxf). 2007 Jun 6; [Epub ahead
of print] PMID: 1755549, in press).
No hotspots have been found in the MEN1 gene; how-
ever, patients from different genetic backgrounds have
shown recurrent mutations in GC-rich regions that are prone
to slippage, suggesting mutational “warm-spot” areas in the
MEN1 gene.33 To date, no relevant genotype-phenotype cor-
relation has been reported.32 Also, interfamilial and
intrafamilial phenotype variability has been demon-
strated.32,33 Thus, relatives of individuals with MEN1 who
harbor the same disease-causing mutation may present dif-
ferent clinical pictures.36
It has been reported that MEN1 mutation could not be
found in up to 30% of familial MEN1 cases genetically
tested.13 Technical limitations or the presence of mutations
in the gene promoter region (which is not usually accessed
in genetic screenings) may explain the finding of geneti-
cally negative MEN1 cases.13 Such a MEN1 mutation pro-
file results in a laborious routine genetic investigation. At
present, genetic screening for MEN1 abnormalities is
mostly available in developed countries.
The MEN1 gene codifies for a 610-amino acid protein
named menin.37 Several tumor suppressor roles of menin
have been disclosed so far, such as, a) cell cycle and cell
growth control, b) transcription regulation, c) DNA repair,
d) genome stability, e) apoptosis regulation, and f) endo-
crine cell proliferation.37,38 A MEN1 germline mutation pre-
disposes the genome to a second mutational event concern-
ing MEN1-associated glands, causing loss of heterozygos-
ity (LOH) of the 11q13 locus. The inactivation of menin is
predicted to disrupt its tumor suppressor molecular path-
ways, thus leading to MEN1 tumorigenesis.37 These find-
ings are consistent with the Knudson’s 2-hit hypothesis for
tumor suppressor genes.39
State of art of MEN1 in Brazil
To date, little information is known about the clinical
and genetic profile of patients with MEN1 in Brazil. As oc-
curs for other syndromes, such as sporadic HPT, for which
specific screening programs are not performed in Brazil,40
it is likely that most patients with MEN1 present as symp-
tomatic, late-diagnosed cases. To our knowledge, no pub-
lic hospital other than Hospital das Clínicas in Brazil is rou-
tinely offering genetic testing for MEN1 gene mutations.
During the last 10 years, patients with MEN1 (and also
MEN2) have been followed at the Disciplina de
Endocrinologia of the Hospital das Clínicas, University of
São Paulo, School of Medicine, at no charge through the Bra-
zilian National System of Health (Sistema Único de Saúde,
SUS). Our unit has developed expertise in diagnosis, man-
agement, and treatment of MEN1, and it has become one of
the reference centers for this disease in Brazil.41–46
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In this study, we report the results of clinical and ge-
netic screenings of patients with MEN1. We also evaluated
the impact of MEN1 genetic screening on the diagnosis and
management of patients with MEN1, before and after its
implementation. As far as we know, this is the first sys-
tematic genetic screening for MEN1 disease performed in
South America.
PATIENTS AND METHODS
This study was approved by local ethics committee.
Written informed consent was obtained from all patients
undergoing genetic testing.
Briefly, the clinical screening of patients with MEN1
at our hospital started in 1997 and comprised the follow-
ing 3 phases: phase 1—systematic clinical identification of
patients with MEN1 at this institution was performed; phase
2—MEN1 genealogies were expanded, and clinical screen-
ing was performed; and phase 3—the genetic testing for
MEN1 was routinely incorporated into the clinical practice
in our unit. The studied patients were followed for 10 years.
Phase 1 – Identification of index cases of MEN1
The criterion for the diagnosis of MEN1 was the pres-
ence of at least 2 MEN1-related tumors in the index cases.1
Hyperparathyroidism (HPT) was identified based on the
presence of hypercalcemia associated with inappropriately
elevated/borderline serum levels of parathyroid hormone
(PTH). Prolactinoma was recognized by consistently high
serum prolactin concentrations, menstrual irregularities,
and/or hypogonadism associated with pituitary adenoma
shown by MRI. Insulinoma was verified by clinical signs
and symptoms of hypoglycemia associated with abnormal
insulin/glucose ratios. Gastrinoma was documented by the
presence of repetitive gastro-duodenal ulcers, gastric acid
hypersecretion, hypergastrinemia, and endoscopic ultra-
sound findings. Somatotrophinoma was diagnosed through
measurements of GH and IGF1; pituitary MRI was also per-
formed. Cushing syndrome was diagnosed by clinical find-
ings, ACTH/cortisol measurements, and image studies.
Other rare involvements such as carcinoid tumors were also
actively sought using standard clinical, biochemical, and
image procedures.
Phase 2 – Clinical screening of relatives at-risk for
MEN1
Familial MEN1 was defined when at least 1 MEN1-re-
lated tumor was found in a first-degree relative. At-risk fam-
ily members were invited to come to the hospital for ex-
ams. Clinical screening for MEN1-related neoplasias was
performed, as recommended by the MEN Consensus.1,13
Annual biochemical exams and a tri-annual imaging inves-
tigation were performed. Those who presented biochemi-
cal or/and imaging abnormalities consistent with MEN1
and who had complaints related to MEN1 symptoms were
diagnosed as affected. Relatives who had MEN1-related fea-
tures at screening but no clinical symptoms were consid-
ered asymptomatic MEN1 cases. Relatives with no com-
plaint and normal biochemical and imaging results were
considered “not conclusive” and were invited to participate
in the annual clinical screening.
Phase 3 – MEN1 genetic analysis
The optimization and standardization of genetic
protocols for MEN1 mutation analysis were established in
2004. Laboratory procedures included, a) genomic DNA
extraction from peripheral blood and oral swabs; b) ampli-
fication of the entire MEN1 coding region (exons 2-10) and
also exon/intron boundaries by polymerase chain reaction
(PCR); c) automated DNA sequencing, and d) MEN1 mu-
tation analysis.
Optimization and standardization of genetic protocols
for MEN1
DNA extraction
After obtaining written informed consent, 10 mL of pe-
ripheral blood were collected (in 2 EDTA-containing tubes)
from the 13 MEN1 probands. Genomic DNA was extracted
according to a standard salting-out protocol or GFX Ge-
nomic Blood DNA Kit (Amersham Bioscience, Piscataway,
NJ, USA). DNA from oral swab samples was obtained us-
ing the Chelex 100® (BioRad).
MEN1 mutation analysis - Optimized protocol
To perform the PCR amplification of the entire coding
region (exons 2-10) and intron/exon boundaries of MEN1,
we used specific primers as previously reported.32,47 To
optimize PCR conditions, we used cycling temperatures and
MgCl2 gradient assays in a MJ PTC-200 thermocycling ap-
paratus (MJ Research). Best results were obtained using 200
ng of genomic DNA, 1X reaction buffer, 2.5 mM MgCl2,
0.5 mM of each dNTP, 0.5 pmol of each primer and 1.25
U of Taq DNA polymerase (Invitrogen, São Paulo) in a to-
tal volume of 30 µL. Thermocycling conditions for the PCR
were optimized as follows: 3 min at 94°C, followed by 30
cycles of 1 min at 94°C, 45 s with a 65°C-to-60°C touch-
down annealing temperature program (minus 1ºC per cy-
cle until 60ºC was reached), and 1 min at 72°C, followed
469
CLINICS 2007;62(4):465-76 The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1
Lourenco Jr DM et al.
by 10 min of final extension at 72°C. The PCR products
were confirmed by electrophoresis on a 1.5% agarose gel
and purified using a Concert Rapid PCR Purification Sys-
tem kit (Life Technologies, Bethesda, MD).
Sequencing reactions were directly performed from pu-
rified PCR products using internal primers for both strands
and Big Dye Terminator v3.1 (Applied Biosystems, Foster
City, CA). Sequencing was carried on an automated
sequencer (ABI Prism 310 DNA Analyzer, Applied
Biosystems, Foster City), according to the manufacturer’s
recommendations. The homology of generated sequences
was obtained using BLAST (http://www.ncbi.nlm.nih.gov/
BLAST). Two sequencing editor software programs (Gene
StudioTM Professional Edition, Suwanee; and Mutation
Surveyour, Softgenetics, PA, USA) were used to identify
DNA abnormalities.
After the identification of the disease-causing MEN1
mutation in an index case, DNA samples from relatives who
participated in the clinical screening (phase 2) were analyzed.
First-degree relatives who did not participate in phase 2 were
contacted and invited to come to the hospital and undergo
the screening. To family members living far from São Paulo
and claiming not to be able to travel, oral swabs were sent
by mail. Furthermore, during the period of the project, sev-
eral local visits were made by a physician (DML) and a so-
cial assistant from our group. They visited at-risk relatives
of MEN1 patients who were interested in participating but
to whom previous procedures were not applicable. This last
approach was also used with families with extended
genealogies living in a small geographic area. A total of 154
samples, 13 from patients who were MEN1 index cases and
141 from at-risk family members of patients with MEN1,
were available for investigation.
Clinical follow-up and genetic counseling were offered
to individuals who tested positive for MEN1 mutation. Fur-
thermore, genetic testing was also offered to their descents.
Individuals who did not inherit the mutant allele were ex-
cluded from MEN1 clinical screening protocol, and they
were informed that their descents would not inherit the fa-
milial predisposition to MEN1-related tumors.
Statistics
ANOVA, Kruskall Wallis, and Mann-Whitney tests were
used when applicable.
RESULTS
In phase 1 of the study, 13 MEN1 index cases were di-
agnosed. All index cases reported a familial history of
MEN1. During phase 2 of the study, 28 patients with MEN1
were diagnosed. During phase 3, 11 MEN1 cases were dis-
covered. These 11 patients decided to undergo clinical
screening only after knowing that they were positive for a
MEN1 mutation.
During the 10-year follow-up of these 13 families involv-
ing 52 individual cases of MEN1, the prevalence of MEN1-
related pathology was as follows: HPT, 94.2% (49/52); pan-
creatic/duodenal endocrine tumors (PETs), 63.5% (33/52);
and pituitary tumors, 51.9% (27/52). Regarding the 49 cases
of HPT, 38 (77.5%) were symptomatic and 11 (22.5%) were
asymptomatic. Gastrinomas were the most common type of
PET (18/33; 54.5%), and 39.0% (7/18) of them were ma-
lignant, as documented by pathology/radiology findings.
Insulinomas (8/33; 24.2%) and exclusively nonsecretory
tumors (7/33; 21.2%) were also represented within PET
cases. Furthermore, prolactinomas were the most frequent
pituitary tumor (18/27; 66.7%), whereas nonsecretory pitui-
tary adenomas (8/27; 29.6%) and somatotrophinoma (1/27;
3.7%) were also present (Table 2).
MEN1 patient groups
The mean ages at diagnosis (clinical or genetic) in groups
I (39.5 ± 15.7 SD years) and II (42.4 ± 15.0 years) did not
significantly differ (P > 0.05). However, when both data were
compared with group III (27.0 ± 14.0 years), significant dif-
ferences were noticed (P = 0.03; P = 0.01, respectively). The
occurrence of 2 major secreting MEN1-related tumors in a
Table 2 - Prevalence of major MEN1-related tumors in
patients with MEN1: index cases (group I), clinically
diagnosed cases (group II), and genetically diagnosed cases
(group III).
group group group total of literature*
I II III patients  (%)
(n = 13) (n = 28) (n = 11) (n = 52)
(%) (%) (%) (%)
parathyroid (HPT) 100 100 72.7 94.2 73-100
pancreas (PETs) 76.9 67.9 27.3 63.5 30-80
 gastrinoma (60)** (57.9)** (33)** (54.6)** 30-75
 insulinoma (50)** (15.8)** (0)** (24.2)** 10-30
 NS (0)** (26.3)** (67)** (21.2)**
pituitary adenoma 69.2 46.4 45.5 51.9 20-40
 prolactinoma (77.8)*** (61.6)*** (60)*** (66.7)*** 62
 NS adenoma (22.2)*** (38.4)*** (20)*** (29.6)*** 15
 somatotrophinoma (0)*** (0)*** (20)*** (3.7)*** 9
ACTHoma 0 0 0 0 4
co-secreting 0 0 0 0 10
carcinoids 7.7 10.7 0 7.7 > 10
HPT, hyperparathyroidism; NS, exclusively nonsecreting
*References1,18,21,28.
** % relative to the cases of pancreatic endocrine tumors (PETs) in this
particular group (one case had both gastrinoma and insulinoma).
***% relative to the cases of pituitary adenomas in this particular group
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single patient tended (P = 0.06) to be more prevalent in
groups I and II, (7/13; 53.8% and 9/28; 32.2%, respectively)
than in group III (1/11; 9.1%). Also, although 3 coexisting
MEN1-related tumors in the same patient were more fre-
quently seen in groups I and II (6/13; 46.2% and 6/28;
21.4%) than in group III (1/11; 9.1%), no significant differ-
ences were noticed (P = 0.22). One isolated MEN1-related
tumor occurred equally in groups II and III (13/28; 46.4%
and 8/11; 72.7%, respectively), as shown in Table 3.
Malignancy and Mortality
Malignancies in MEN1-related tumors were documented
by the pathologic findings in 8 cases (data not shown) and/
or by the presence of either local or distant metastases in
all of them. Malignant tumors were equally represented in
groups I (3/13, 23.1%) and II (5/28, 17.9%). Metastases
originated from gastrinomas (6/8; 75%) or carcinoid tumors
(2/8; 25%). No patient in group III exhibited a malignant
MEN1-related tumor (Table 3).
All 4 patients with carcinoid tumors were asymptomatic.
The first patient had a gastric carcinoid that was identified
and removed by endoscopy. The second had a bronchial car-
cinoid presenting local lymph node metastasis and underwent
surgery. The third patient presented with an atypical, multi-
ple metastatic pulmonary carcinoid, and the fourth had a pul-
monary carcinoid tumor, but he refused any kind of treatment.
In the 10-year follow-up period (1997-2006), 4 of the
52 patients died of causes related to MEN1 disease as fol-
lows: 2 out of the 13 patients in group I (15.4%) and 2 out
of the 28 patients in group II (7.1%). Three of them died
due to metastatic gastrinoma, and 1 due to secondary com-
plications of a nonsecretory pituitary macroadenoma. No
death in group III has occurred (Table 3).
MEN1-related tumor prevalence
Primary hyperparathyroidism was diagnosed in all pa-
tients in groups I and II (100%) and in 8 patients (72.7%)
in group III. Asymptomatic HPT was present in patients
from groups I (7.7%) and II (21.4%), but it prevailed in
group III (50%). Conversely, symptomatic HPT (nephro-
lithiasis) was seen mostly in patients of groups I and II
(87.8%) and was less represented in group III (50%).
The prevalence of pancreatic/duodenal endocrine tumors
(PETs) in groups I and II (76.9% and 67.9%, respectively)
was higher than in group III (27.3%). Within PET cases,
gastrinoma was mostly present in groups I (60%) and II
(57.9%) and less observed in group III (33%). Most
insulinomas were documented in groups I (50%) and II
(15.8%) and were absent in group III. Conversely, exclusively
nonsecretory PETs were only seen in groups III (67%) and
II (26.3%).
Furthermore, in our patients with MEN1, pituitary ad-
enomas were mostly diagnosed in group I (69.2%) and were
equally represented in groups II (46.4%) and III (45.5%).
In all 3 groups, prolactinoma was highly prevalent (77.9%,
61.6%, and 60%, respectively). Nonsecretory adenomas
comprised 22.2%, 38.5%, and 20%, respectively.
Taking into account patients from all 3 groups, most
MEN1 cases (73.1%) were recognized after diagnosis of
symptomatic HPT, as this condition was highly prevalent
in all groups (92.3%, 78.6%, 50%, respectively). Moreo-
ver, symptomatic PET cases were significantly more fre-
quent in groups I and II (50%: 76.9%) than in group III
(9%; P < 0.05). Furthermore, symptomatic pituitary tumors
were documented in all 3 groups (61.5%, 28.6%, and
36.4%, respectively).
Furthermore, the annual clinical screening for MEN1
reported here allowed us to diagnose 29 asymptomatic
MEN1-related tumors, as follows: 11 patients with HPT;
7 patients with non-secretory pancreatic endocrine tumors,
7 patients with non-secretory pituitary tumors, and 4 pa-
tients harboring malignant, asymptomatic carcinoid
tumors.
Furthermore, after performing the genetic screening, 11
Table 3 - Clinical manifestations of MEN1 in patients with MEN1: index cases (group I), clinically diagnosed cases
(group II), and genetically diagnosed cases (group III).
probands(index cases) patients diagnosed by familial patients diagnosed by MEN1
(group I) clinical screening(group II) genetic testing(group III)
Mean age at diagnosis (years) 39.5 (18-74) 42.4 (18-61) 27 (14-56) *
0 MEN1-related tumor - - 1 (9.1%)
1 MEN1-related tumor - 13 (46.4%) 8 (72.7%)
2 MEN1-related tumors 7 (53.8%) 9 (32.2%) 1 (9.1%) **
3 MEN1-related tumors 6 (46.2%) 6 (21.4%) 1 (9.1%)
Tumor stage advanced early / advanced asymptomatic / early
Malignancy 3 (23%) 5 (17.9%) no metastasis
Mortality 2 (15.4%) 2 (7.1%) no death
*P < 0.05; **p = 0.06
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MEN1 mutation carriers were identified and included in the
annual clinical follow-up.
GENETIC RESULTS
Germline mutations in patients with MEN1 from HC-
FMUSP
The following disease-causing mutations where found
through MEN1 mutation analysis: 308del1 (exon 2), proband
1; 375del21 (exon 2), proband 2; I147F (exon 2), proband
3, 360del4 (exon 2), probands 4 and 5; 1059del1 (exon 7),
proband 6; 1243del1 (exon 8), proband 7; 1348T>G (exon
9), proband 8; 1351T>C (exon 9), proband 9; 1353C>T
(exon 9), proband 10; 1523G>T (exon 10), proband 11;
1689C>T (exon 10), proband 12; and IVS3+1 G>T (exon
2), proband 13 (Figure 1; Toledo RA et al., Clin Endocrinol
(Oxf). 2007 Jun 6; [Epub ahead of print] PMID: 1755549,
in press). All mutations were confirmed using a second DNA
sample from an independently collected blood sample.
No mutational hot spot was found. Mutations of MEN1
were found at exons 2, 7, 8, 9, and 10; also, 1 splicing mu-
tation was identified at intron 3. All identified MEN1 muta-
tions were predicted to cause disruption of menin’s transcrip-
tional regulation or menin’s protein interactions and thus lead
to MEN1 tumorigenesis (Toledo RA, data not shown).
Additionally, we performed genetic testing of 141 rela-
tives at-risk for MEN1. Thirty-nine relatives were identi-
fied as mutation carriers: 28 had previously undergone
clinical exams (symptomatic cases), and 11 had not par-
ticipated in the previous clinical screening. These 11 rela-
tives after learning that they were positive for a MEN1 mu-
tation agreed to adhere to the clinical screening. One hun-
dred and one (101/102, 99%) relatives who were negative
for a MEN1 mutation did not present MEN1-related com-
plaints or symptoms, while 1 (1%) developed sporadic pri-
mary HPT (MEN1 phenocopy).
DISCUSSION
Multiple endocrine neoplasia type 1 is an inherited dis-
Figure 1 - The coding region (exons 2-10) of the MEN1 gene. MEN1 mutations identified in 13 MEN1 index cases are indicated. The mutation 360del4 was
localized in 2 unrelated patients with MEN1.
order with high penetrance, resulting in parathyroid, en-
docrine-pancreas/duodenum, and pituitary tumors.1,2 Sev-
eral other benign and malignant, endocrine and
nonendocrine tumors have also been described for patients
with MEN1. However, to date, very few data are available
on patients with MEN1 from countries outside of North
America, Europe, Japan, and Australia. In this report, we
present the results of clinical and genetic MEN1 screen-
ings performed in Brazil over a 10-year period. Also, we
document important changes in the clinical presentation of
patients with MEN1 after the implementation of the MEN1
genetic diagnosis.
Clinical manifestations in our MEN1 series are in ac-
cordance with those in the literature (Table 2). Thus, HPT
was the most frequent (94.2%) and usually the first mani-
festation of MEN1, as reported by Trump et al.3 The preva-
lence of PETs in our 52 MEN1 cases was as high as 63.5%,
and in groups I (76.9%) and II (67.9%) it was higher than
in group III (27.3%). The prevalence of pituitary adenomas
in our MEN1 series (51.9%) was slightly higher than pre-
viously reported (20%-40%, Table 2); however, our sam-
ple is still relatively limited for further conclusions. Finally,
carcinoid tumors were equally presented in our patients and
data from the literature (Table 2).
In this study, we were able to implement MEN1 muta-
tion analysis in clinical practice. The genetic screening suc-
cessfully identified MEN1 mutations in all 13 MEN1 in-
dex cases (Figure 1). Moreover, all 12 different MEN1
germline disease-causing mutations we identified are pre-
dicted to inactivate the tumor suppressor functions of menin
and lead to MEN1 tumorigenesis. Although probands 4 and
5 had recurrent MEN1 mutations, no hot spot was found;
mutations were spread throughout the coding and
noncoding regions of the gene. This finding confirmed the
need for searching the entire MEN1 coding region as well
as its introns, which makes MEN1 genetic screening a la-
borious routine procedure. So far, genetic screenings for
MEN1 have been performed in developed countries,
whereas no such a program had so far been implemented
in South America. Our data should be useful for improv-
ing management of the MEN1 syndrome in Brazil.
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The familial genetic screening included 141 family
members at risk for MEN1 and has identified those who
should undergo annual clinical surveillance of MEN1-re-
lated tumors and those who should be ruled out from clini-
cal screening. Both positive and negative genetic results
were worthwhile and highly informative in the management
of individuals at risk for MEN1. The 39 at-risk relatives
who inherited the affected MEN1 allele underwent complete
surveillance for MEN1-related tumors. Furthermore, MEN1
genetic testing ruled out 102 family members who did not
harbor a MEN1 mutation (and had no susceptibility for de-
veloping MEN1-associated neoplasias) from unnecessary
following-ups, avoiding unnecessary, expensive exams and
lifelong surveillance (Figure 2).
Genetic testing was also important for confirming
MEN1 disease in previously diagnosed family members.
Among such cases, we tested 1 relative presenting a pri-
mary HPT, who did not harbor a germline MEN1 mutation.
According to MEN1 clinical criteria, this patient should
have been diagnosed as a MEN1-affected case. However,
he was indeed a sporadic HPT case. Such rare cases are
called MEN1 phenocopies and do not need further surveil-
lance for MEN1.44,48,49 In the other hand, genetic testing for
MEN1 mutations might disclose inherited cases within
“sporadic” patients presenting either HPT at early ages (<
30 yr) or recurrent HPT. The latter patients should be ge-
netically tested, and if a germline mutation is detected, a
total parathyroidectomy followed by an autograph to the
forearm or subtotal parathyroidectomy should be per-
formed, instead of adenomectomy.1
It is largely accepted that the earlier the detection of
neoplasias, the better is its management. Patients who are
symptomatic for MEN1 usually require more aggressive
and risky surgeries and a higher number of exams (Table
4). Also, the chance of cure could be reduced in late-diag-
nosed cases.16,17,25 Despite that, the identification of MEN1
mutations has been reported to have a limited influence in
guiding early therapeutic surgery1,13; however, our data have
shown a relevant impact of MEN1 genetic screening in the
management of at-risk patients. Importantly, we noticed a
shift towards milder clinical presentations in our 11 geneti-
cally diagnosed MEN1 patients. These patients (group III)
presented different phenotypes from the clinically diag-
nosed patients (groups I-II) as follows, a) they were sig-
nificantly (11-15 years) younger; b) they were usually
asymptomatic; c) they mostly presented only 1 or no MEN1
tumor; d) they tended to present MEN1 tumors at their early
stages; e) they had no MEN1-related malignancy; and f)
Figure 2 - MEN1 screening program.
Table 4 - Usual major clinical manifestations of MEN1 at its early and late stages. Appropriate treatments for early- and
late-diagnosed MEN1 patients are listed.
Early recognition of MEN1 Late recognition of MEN1
Major MEN1 manifestations Clinical features Treatment Clinical complications Treatment
Hyperparathyroidism PTH Ca++ total parathyroidectomy* renal complications osteoporosis, renal dialysis or
renal calculi, renal insufficiency transplant
Insulinoma insulin  glycemia, surgery hypoglycemic shock, neuro- surgery
hypoglycemic symptoms psychiatric disorders, metastasis (10%)
Gastrinoma gastrin, gastritis, ulcer, gastric drug therapy surgery esophageal stenosis, surgery chemotherapy
acid hypersecretion gastroduodenal ulcers, metastasis interpheron somatostatin
(60%) analogues
Prolactinoma microadenoma drug therapy infertility, osteoporosis, hypogonadism, drug therapy
macroadenoma,visual defects, radiotherapy surgery
Thymic carcinoid - preventive thymectomy metastasis surgery chemotherapy
radiotherapy
*with autograph to the forearm
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they all remained alive during the follow-up period (Ta-
bles 2-3). Our present findings corroborate a previous pro-
spective study documenting that genetically diagnosed
MEN1 patients have biochemical evidence 10 years preced-
ing the signs and symptoms of the disease.50
Therefore, the implementation of a genetic screening pro-
gram for MEN1 in a reference health center, such as our hos-
pital, would be an important step for improving the man-
agement of this complex disease in Brazil. This program is
a new effort among many others in the study of cancer and
cancer prevention in Brazil.51–56 Also, such a program would
save significant amounts of money spent on surveillance of
patients that are negative for a MEN1 mutation.
In conclusion, we present the first clinical and genetic
MEN1 screening trial performed in South America. Our
study shows that MEN1 genetic testing greatly contributes
to a more adequate clinical management of this complex
syndrome and may benefit patient care.
RESUMO
Lourenco Jr. DM, Toledo RA, Coutinho FL, Margarido LC,
Siqueira SAC, Cortina MA, Montenegro FL, Machado MC,
Toledo SP. Impacto do rastreamento clínico e genético para
Neoplasia Endócrina Múltipla tipo 1. CLINICS.
2007;62(4):465-76.
OBJETIVOS: Realizar rastreamentos clínico e gênico para
Neoplasia Endócrina Múltipla tipo 1 (NEM1) e analisar seu
impacto no seguimento clínico desses pacientes no Hospi-
tal das Clínicas, SP.
MÉTODOS: O diagnóstico clínico de NEM1 foi realizado
de acordo com o Consenso sobre neoplasias endócrinas
múltiplas. A análise genética para identificação de
mutações foi realizada por sequenciamento automático de
todas as regiões codificadoras e fronteiras exon/intron do
gene MEN1. Os casos afetados foram sub-divididos em 3
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